| Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 17064208 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Uncontrolled diabetes mellitus is associated with both microvascular and macrovascular complications. Despite an array of treatment options available, achievement of euglycemia in most patients with diabetes is still lacking. Pramlintide acetate, a synthetic analog of the human hormone amylin and belonging to a new class of agents, was approved in March 2005 as adjunctive treatment in patients with type 1 or 2 diabetes mellitus. To evaluate the data available on the efficacy and safety of pramlintide, we conducted a search of MEDLINE (January 1966-May 2006) and International Pharmaceutical Abstracts (January 1970-May 2006). Bibliographies of clinical trials were reviewed for additional references. The literature reviewed demonstrated that pramlintide is effective in reducing levels of glycosylated hemoglobin and potentially preventing weight gain. The most commonly reported adverse effects associated with pramlintide were nausea, anorexia, and hypoglycemia. These adverse effects occurred more often during the initiation of therapy and were usually mild to moderate in nature. Whether this therapy is a cost-effective option for patients with type 1 or type 2 diabetes mellitus is yet to be determined. |
| | |
Authors:
|
Anna Nogid; David Q Pham |
Related Documents
:
|
3914808 - Role of plasma c-peptide determination in the management of type ii diabetes. 11334398 - Intravenous immunoglobulin therapy for diabetic amyotrophy. 23375408 - Insulin-like growth factor and the etiology of autism. 17102158 - Insulin treatment and the problem of weight gain in type 2 diabetes. 21691558 - Elevated pancreatic enzymes, igm, soluble interleukin-2 receptor in anti-gadab(+) type ... 18773798 - Determinants of quality of life in primary care patients with diabetes: implications fo... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Pharmacotherapy Volume: 26 ISSN: 0277-0008 ISO Abbreviation: Pharmacotherapy Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-10-26 Completed Date: 2007-01-10 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: United States |
Other Details:
|
Languages: eng Pagination: 1626-40 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York 11201-5497, USA. anna.nogid@liu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amyloid
/
adverse effects,
pharmacokinetics,
secretion,
therapeutic use* Clinical Trials as Topic Diabetes Mellitus, Type 1 / drug therapy*, metabolism Diabetes Mellitus, Type 2 / drug therapy*, metabolism Hemoglobin A, Glycosylated / metabolism Humans Hypoglycemic Agents / adverse effects, pharmacokinetics, therapeutic use* Insulin / secretion |
| Chemical | |
Reg. No./Substance:
|
0/Amyloid; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 106602-62-4/amylin; 11061-68-0/Insulin; 151126-32-8/pramlintide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management of antiplatelet therapy for minimization of bleeding risk before cardiac surgery.
Next Document: Povidone-iodine-induced burn: case report and review of the literature.